- Reaction score
- 732
Kintor Pharmaceuticals just got their IND application for their new drug GT20029 approved by the NMPA.
What is GT20029?
«GT20029 is an AR degrader that degrades the AR protein. The mechanism of action of GT20029 is to recruit the AR protein to the E3 ubiquitin ligase for degradation. It acts on the local tissues of the peripheral skin and local hair follicle sebaceous glands, which reduces the sensitivity of AR to androgens without systemic exposure to the drug.»
http://gamma.euroland.com/tools/ch/?app=news&at=ATTOPEN&oid=3868135&l=EN&na=ami062@uit.no&ru=http://asia.tools.euroland.com/tools/subscriptioncentre2/tracker/attachment/?atid=1280030&url=SG9uZ0tvbmdcRXRuZXRcMjAyMS0wMlxIS0VYLUVQU18yMDIxMDIwMV85NjA4ODg5XzAuUERG&companycode=KY-9939&isstockexchangerelease=1
What is GT20029?
«GT20029 is an AR degrader that degrades the AR protein. The mechanism of action of GT20029 is to recruit the AR protein to the E3 ubiquitin ligase for degradation. It acts on the local tissues of the peripheral skin and local hair follicle sebaceous glands, which reduces the sensitivity of AR to androgens without systemic exposure to the drug.»
http://gamma.euroland.com/tools/ch/?app=news&at=ATTOPEN&oid=3868135&l=EN&na=ami062@uit.no&ru=http://asia.tools.euroland.com/tools/subscriptioncentre2/tracker/attachment/?atid=1280030&url=SG9uZ0tvbmdcRXRuZXRcMjAyMS0wMlxIS0VYLUVQU18yMDIxMDIwMV85NjA4ODg5XzAuUERG&companycode=KY-9939&isstockexchangerelease=1